GI Doc Awakes to Bat in Mouth; Stopped Farting? Uh-Oh; FDA Approves GERD Implant

A gastroenterologist from Virginia, Dr. Krista Edelman, recently made headlines after she awoke to a bat attempting to enter her mouth during a colonoscopy procedure. This surprising incident garnered attention on social media platforms.

A recent randomized trial conducted by American researchers suggests that performing a second forward-view examination of the right colon using artificial intelligence can improve the detection of adenomas during colonoscopy.

In an effort to promote better adherence to guideline-recommended intervals for colonoscopy, a center implemented an electronic health record intervention.

Gastroenterologist Trisha Pasricha, MD, shared concerning signs that may necessitate a visit to the emergency department, such as experiencing no more flatulence or noticing black, shiny stool.

A randomized trial supported the use of SI-449, a cross-linked, powder-formed, chondroitin sulfate adhesion barrier system, as a new option during open rectal resections.

It has been noted that a significant number of children with Crohn's disease are not receiving adequate treatment with 5-aminosalicylates, according to research published in Clinical Gastroenterology and Hepatology.

Recent findings in Immunity shed light on intestinal inflammation, tissue regeneration, the extracellular matrix, and their connections to inflammatory bowel diseases.

There is growing support for leveraging patient-reported outcomes to monitor Crohn's disease activity within clinical settings, as suggested by a study in Gastro Hep Advances.

An Italian study provided reassurance regarding the switch from brand name ustekinumab (Stelara) to its biosimilars in the treatment of Crohn's disease, as reported in Clinical Gastroenterology and Hepatology.

A phase III trial of tezepelumab (Tezspire), developed by AstraZeneca and Amgen, met its co-primary endpoints in patients with eosinophilic esophagitis.

The FDA granted premarket approval to RefluxStop, a non-drug implant device designed to treat gastroesophageal reflux disease (GERD), according to the manufacturer, Implantica.

In a phase II trial, a novel thyroid hormone receptor β agonist (ALG-055009) showed promise in reducing liver fat in patients with metabolic dysfunction-associated steatohepatitis (MASLD) without encountering safety issues, according to research published in the Lancet Gastroenterology & Hepatology.

MASLD remains relatively unknown to many people, as indicated by U.K. survey data published in Clinical Gastroenterology and Hepatology.

A study of patients screened for MASLD trials revealed that approximately one in ten individuals had phosphatidylethanol levels that would warrant evaluation for alcohol-related liver disease, as reported in Clinical Gastroenterology and Hepatology.

In a study of U.S. veterans with hepatitis C-related decompensated cirrhosis, 13% experienced recompensation after commencing direct-acting antivirals, according to research published in Clinical Gastroenterology and Hepatology.

An investigational selective immunoproteasome inhibitor, zetomipzomib, demonstrated potential in a phase II study for treating difficult-to-manage autoimmune hepatitis, as reported in Hepatology.

Research published in the Journal of Hepatology examined the 3-year outcomes of patients in a phase III study that supported the approval of elafibranor (Iqirvo) for primary biliary cholangitis.